Cardo Medical, Inc. Appoints Stephen Liu, M.D. to Board of Directors

Share this story with your network

LOS ANGELES, May 18, 2010 (GlobeNewswire via COMTEX) — Cardo Medical, Inc.(CDOM 0.96, 0.00, 0.00%), an orthopedic medical device company based in Beverly Hills, California, announced today that Dr. Stephen Liu, a well-respected orthopedic surgeon, was appointed to its Board of Directors on April 8, 2010. Dr. Liu currently serves as Chairman and Chief Executive Officer of ChiMed, Inc., a visual health content provider for consumers in Asia, and Chairman of First China Capital Partners, a boutique merchant bank based in China, Hong Kong, and Taiwan. From 1992 until 2006, Dr. Liu served on the faculty at the UCLA School of Medicine, and was a team physician staff member for UCLA athletics for 8 years. During Dr. Liu’s time at UCLA, Dr. Liu was a clinical advisor to multiple major medical device companies.

“We are delighted to welcome an exceptional orthopedic surgeon like Dr. Stephen Liu to our Board,” said Andrew Brooks, M.D., Chairman and CEO of Cardo Medical. “We expect Dr. Liu’s insight and experience, both clinically and as a businessman, will be valuable as Cardo Medical grows and expands its product lines.”

Dr. Phillip Frost M.D., Chairman of Teva Pharmaceuticals, and CEO of OPKO Health, said, “I am pleased to have Dr. Liu join the Cardo board, as the company shifts its emphasis from research and development to marketing and sales. We anticipate Dr. Liu’s relationships to impact our strategy for Asia, particularly Taiwan and China.” Dr. Liu received his M.D. degree from the University of Southern California School of Medicine, and trained as an orthopedic surgeon specializing in Sports Medicine. In 1996, Dr. Liu was awarded the European Sports Medicine Traveling Fellow, and in 1997, Dr. Liu won the National Cabaud Basic Science Award for research on the (i) identification of Estrogen receptors on the anterior cruciate ligament and (ii) effects of Estrogen on collagen metabolism.

About Cardo Medical, Inc.

Cardo Medical, Inc. (CDOM 0.96, 0.00, 0.00%) is an orthopedic medical device company specializing in designing, developing and marketing high performance reconstructive joint devices and spinal surgical devices. Reconstructive joint devices are used to replace knee, hip and other joints that have deteriorated through disease or injury. Spinal surgical devices involve products to stabilize the spine for fusion and reconstructive procedures. Within these areas, we are focused on developing surgical devices, instrumentation and techniques that will enable surgeons to move what are typically inpatient surgical procedures to the outpatient world. We commercialize our reconstructive joint devices through our Reconstructive division and our spine devices through our Spine division.

Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website atwww.cardomedical.com for more information on our complete portfolio of Reconstructive and spine devices.

This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding Cardo Medical’s business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in current and future funding, recent changes to healthcare policy and the U.S. healthcare system, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. Cardo Medical’s forward looking statements speak only as the date of this press release or when made and Cardo Medical does not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Cardo Medical

Leave a Comment

Your email address will not be published. Required fields are marked *

*